Category: Biotech

Biotech • 10.10.25

Bristol Myers Squibb's $1.5 Billion Bet: A New Frontier in RNA and Cell Therapy

Bristol Myers Squibb's $1.5B acquisition of Orbital Therapeutics signals a major shift towards RNA and cell therapy platforms, impacting biotech M&A and drug development.

StockTimes Content Team

1
Finance • 07.03.25

U.S. Stocks and Bitcoin: A Tale of Diverging Fortunes Post-Election

StockTimes Content Team
Cryptocurrency • 19.04.25

Legal Experts Advocate for Flexible SEC Token Classification Framework

StockTimes Content Team
Cryptocurrency • 08.03.25

XRP, ADA, SOL Plummet as White House Crypto Summit Disappoints Traders

StockTimes Content Team
Finance • 15.03.25

Mütterrente Expansion: A Costly Redistribution or a Necessary Reform?

StockTimes Content Team
Politics • 27.04.25

BSW Power Struggle: Sahra Wagenknecht Fails to Oust Katja Wolf as Thuringian Leader

StockTimes Content Team
Regulation • 08.10.25

A New Dawn for Digital Assets: The SEC's Push for an Innovation Exemption

StockTimes Content Team

Categories

Tags